Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Re: Red Acre Investments: Positive Trials But Further Capital Raisies Ahead

If the trial data is as good as Al intimates, (or superiority rules the day) I think Redacres estimates are WAY conservative for a new 1st line therapy for a $65 BILLION worldwide market. Mannkind gets bought out by a BigPharm who can build out manufacturing from pocket change.

Share
New Message
Please login to post a reply